Routine Genetic Polymorphism Testing in Adult Sepsis: Not Recommended
Routine testing for genetic polymorphisms should NOT be performed in adult patients with sepsis, as it does not currently impact clinical management or improve patient outcomes. The Surviving Sepsis Campaign guidelines (2016/2017) make no recommendations regarding genetic testing for sepsis management 1, 2, 1, 2.
Why Genetic Testing Is Not Part of Standard Care
Guideline Evidence
The most authoritative and recent guidelines—the Surviving Sepsis Campaign International Guidelines (2016)—provide comprehensive recommendations for sepsis management across all domains including:
- Initial resuscitation and fluid management
- Antimicrobial therapy
- Vasopressor support
- Mechanical ventilation
- Blood product administration
- Corticosteroid use
Notably absent from these guidelines is any mention of genetic polymorphism testing 1, 2, 1, 2, 1. This omission is deliberate and reflects the lack of actionable clinical utility.
Research Context vs. Clinical Reality
While research has identified numerous genetic variants associated with sepsis susceptibility and outcomes, these findings have not translated into clinical practice:
Research findings show:
- Multiple polymorphisms in genes like TNF-α, IL-1β, IL-6, IL-10, TLR-4, CD14, and CXCR2 are associated with sepsis risk 3, 4, 5, 6, 7
- Polygenic risk scores can achieve reasonable discrimination (c-statistic ~0.75) 3
- Most genetic variants have small individual effect sizes 3
Critical limitations preventing clinical use:
- No therapeutic interventions are currently available that can be tailored based on genetic polymorphism results
- Turnaround time for genetic testing (days to weeks) is incompatible with the urgent nature of sepsis management, where antimicrobials must be started within 1 hour 2
- Lack of standardization in which polymorphisms to test and how to interpret results
- No evidence that genetic testing improves mortality, morbidity, or quality of life outcomes
- Cost-effectiveness has not been established
Current Standard of Care
Focus clinical efforts on evidence-based interventions that DO impact outcomes:
Immediate Actions (Within 1 Hour)
- Obtain blood cultures before antibiotics (if no substantial delay) 2
- Administer broad-spectrum IV antimicrobials 2
- Begin fluid resuscitation with at least 30 mL/kg crystalloid 2
- Initiate vasopressors if hypotensive despite fluids (target MAP ≥65 mmHg) 2, 1
Risk Stratification Tools
Use validated clinical tools rather than genetic testing:
- Severity scores (APACHE, SOFA)
- Lactate levels for tissue hypoperfusion 2
- Clinical examination and hemodynamic assessment 2
Future Considerations
Genetic testing may eventually have a role if:
- Rapid point-of-care genetic tests become available (results within minutes)
- Specific therapies are developed that target particular genetic variants
- Prospective trials demonstrate improved outcomes with genotype-guided therapy
The genomics field is advancing 8, but implementation requires infrastructure for variant interpretation, reimbursement mechanisms, and most importantly, actionable therapeutic options—none of which currently exist for sepsis.
Common Pitfall to Avoid
Do not delay standard sepsis treatment to pursue genetic testing. Every hour delay in antimicrobial administration increases mortality. The evidence-based bundle of care (early antibiotics, fluid resuscitation, source control, vasopressors when needed) remains the cornerstone of sepsis management and has proven mortality benefit 1, 2.